MBX Biosciences (MBX) Accounts Payables (2023 - 2026)

MBX Biosciences has reported Accounts Payables for 4 years, with the latest figure at $7.0 million in Q1 2026.

• Quarterly Accounts Payables rose 64.29% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (up 64.29% YoY) and the FY2025 annual result came in at $3.0 million, down 44.2% from the prior year.
• Accounts Payables improved to $7.0 million in Q1 2026 per MBX's latest filing, from $3.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $7.0 million in Q1 2026 and troughed at $1.4 million in Q4 2023.
• A 4-year average of $4.4 million and a median of $4.6 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables jumped 283.54% in 2024, then slumped 44.2% in 2025.
• Over 4 years, Accounts Payables stood at $1.4 million in 2023, then surged by 283.54% to $5.3 million in 2024, then plunged by 44.2% to $3.0 million in 2025, then surged by 134.26% to $7.0 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $7.0 million, $3.0 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.